Pharmaceutical polymorph patents are regarded as effective means and important secondary pharmaceutical patents to extend the life cycle of pharmaceutical patent protection. However, the inventiveness evaluation criteria for pharmaceutical polymorph patents have become much stricter in China while the amount of patent application keeps soaring. The clinical research of pharmaceutical polymorphs commenced in 1950s internationally…

1       Background In the past several years, the Supreme People’s Court (“SPC”) of China has been working on establishing a precedent system appropriate for China.  In 2010, the SPC launched the Guiding Cases System (“GCS”).  Under the GCS, the SPC each year selects and publishes certain representative cases from all level of courts as Guiding…

A positive view is spreading on post-filing experimental data in China since the recent official post of the proposed revisions to the Guidelines for Patent Examination (the “Guidelines”) by the State IP Office (the “SIPO”) of China.  People tend to think that the window is about to open to post-filing experimental data, just like it…

In an effort to further enhance protection of Intellectual Property Rights (IPRs) and to promote implementation of the innovation-driven development strategy, the State Intellectual Property Office (SIPO) of China posted online proposed revisions to Guidelines for Patent Examination to solicit public opinions from 28 October to 27 November 2016. The new guidelines are expected to…